(Q45710911)

English

Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge

scientific article published on October 15, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge (English)

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

0 references

object named as

vaccinia virus

1 reference

based on heuristic

inferred from title

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Robert F. Siliciano

8

object named as

Robert F Siliciano

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

4

object named as

Simon F Lacey

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Corinna La Rosa

5

object named as

Corinna La Rosa

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

9

object named as

Don J Diamond

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

author name string

Pirouz Daftarian

1

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Saima Ali

2

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Rahul Sharan

3

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Jeff Longmate

6

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Christopher Buck

7

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

language of work or name

0 references

publication date

1 October 2003

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

15 October 2003

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14530323

18 March 2024

full work available at URL

Journal of Immunology

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

171

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

4028-4039

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection

1

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

HIV-1-specific cellular immune responses among HIV-1-resistant sex workers

2

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi.

3

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects

4

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors

5

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

6

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif

7

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery

9

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

10

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Reduction of respiratory syncytial virus titer in the lungs of mice after intranasal immunization with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide

11

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine

12

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques

13

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Adjuvants--a balance between toxicity and adjuvanticity

14

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Adjuvants designed for veterinary and human vaccines

15

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses

16

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants

17

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites

18

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

A Toll-like receptor recognizes bacterial DNA

19

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice

20

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes

21

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1.

23

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein

25

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation.

26

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors

27

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.

28

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

29

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

30

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies

31

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice

32

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.

33

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries

34

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

The use of transgenic mice to generate high affinity p53 specific cytolytic T cells.

36

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus.

38

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization

39

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Degradation signals in the lysine-asparagine sequence space

40

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques

41

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.

42

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes

43

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

44

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Immunologic and proteolytic analysis of HIV-1 reverse transcriptase structure

45

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses

46

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge

48

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides

50

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes.

51

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein

52

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles

54

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Ubiquitin fusion technique and its descendants

55

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Mechanisms of cytokine synergy essential for vaccine protection against viral challenge

56

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs

58

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1

59

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice

60

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals

61

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual

62

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

HIV-specific cytotoxic T lymphocytes in seropositive individuals

64

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides

65

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion

68

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus

69

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection

70

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles

71

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection

73

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Temporal loss of Nef-epitope CTL recognition following macaque lipopeptide immunization and SIV challenge

75

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Vaccination to treat persistent viral infection

76

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

77

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.

78

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection

79

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism

81

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity

82

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence

83

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

84

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL.

85

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity

87

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses.

88

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques

92

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

93

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine

94

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection

95

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals

97

1 reference

10.4049/JIMMUNOL.171.8.4028

https://api.crossref.org/works/10.4049/JIMMUNOL.171.8.4028

18 March 2024

Identifiers

10.4049/JIMMUNOL.171.8.4028

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45710911&oldid=2107844379"